1. Scrip
  2. >>Business
  3. >>Earnings

As Vaccine Revenues Flow In, BioNTech Makes Rapid Oncology Push

German Biotech Initiates Multiple IO Programs

 
• By Alaric DeArment

The company also is adding new capabilities, including a cell therapy platform, and it is investing in AI and machine learning, like fellow mRNA player and COVID-19 vaccine maker Moderna.

shutterstock-264802244
BioNTech is doing a major push into immuno-oncology • Source: Shutterstock

BioNTech SE’s claim to fame may be the COVID-19 vaccine it developed with partner Pfizer Inc., but looking beyond the pandemic, the German biotech especially wants to make its presence known in the immuno-oncology space as it ramps up development of several product candidates and platforms in various cancers, including under partnerships with makers of checkpoint inhibitors. To that end, the company has made some significant investments.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

AstraZeneca Logs Japan Growth Despite Price Cuts

 
• By Lisa Takagi

AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.

Taxes, Not Tariffs, Influence US Manufacturing, J&J CEO Says

 
• By Jessica Merrill

The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Regulatory And Macroeconomic Uncertainty Hang Over Q1 Earnings Season

 
• By Jessica Merrill

As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.

More from Business

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.